Company news
Telo Genomics Corp. news in 2026
Telo Genomics Corp.'s news releases, calls and decks from 2026, newest first.
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
October 29, 2026
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
September 29, 2026
Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
September 15, 2026
Telo Genomics Grants Stock Options
August 4, 2026
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
July 16, 2026
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
July 9, 2026
Telo Genomics Announces Termination of Investor Relations Agreement
June 26, 2026
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
April 14, 2026
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
March 31, 2026
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
March 9, 2026
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
February 27, 2026
Telo Genomics Closes First Tranche of Convertible Debentures Financing
February 18, 2026
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
January 29, 2026
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
January 19, 2026